Emerging Evidence on the Treatment of Obesity


In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.

1:20 Obesity-associated metabolic disturbances

5:37 When to start medication for obesity

8:28 Metabolic pathways leading to weight gain

13:19 Long-term impact of weight fluctuations

16:07 GLP-1 agonists for weight loss

20:26 Insurance coverage for anti-obesity medications (AOMs)

24:50 Combining lifestyle changes with AOMs

26:27 ‘Super-responders’ to GLP-1 agonist therapies

30:51 Non-responders to GLP-1 agonist therapies

37:28 Comprehensive approach to weight management

Related Videos
Optimizing Diabetes Therapies with New Classifications
Helen Colhoun, MD | Credit: University of Edinburgh
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Payal Kohli, MD | Credit: Cherry Creek Heart
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
© 2024 MJH Life Sciences

All rights reserved.